Who are AG-73305's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Itovebi, Piqray, Placebo followed by Fisetin, SHR0302, TGR-1202, P-3073.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ag-73305.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AG-73305 — Competitive Intelligence Brief

AG-73305 (AG-73305) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K/mTOR inhibitor. Area: Oncology.

phase 2 PI3K/mTOR inhibitor PI3K Oncology Biologic Live · refreshed every 30 min

Target snapshot

AG-73305 (AG-73305) — Allgenesis Biotherapeutics Inc.. AG-73305 is a small molecule inhibitor of the PI3K/AKT/mTOR pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AG-73305 TARGET	AG-73305	Allgenesis Biotherapeutics Inc.	phase 2	PI3K/mTOR inhibitor	PI3K
Itovebi	inavolisib	Pfizer	marketed	Kinase Inhibitor [EPC]	phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)	2024-01-01
Piqray	alpelisib	Novartis	marketed		PI3Kα	2019-01-01
Placebo followed by Fisetin	Placebo followed by Fisetin	Wake Forest University Health Sciences	marketed	Senolytic agent	Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
SHR0302	SHR0302	Jiangsu HengRui Medicine Co., Ltd.	phase 3	PI3K inhibitor	PI3K
TGR-1202	TGR-1202	Vanderbilt-Ingram Cancer Center	phase 3	PI3K delta inhibitor	PI3K delta
P-3073	P-3073	Polichem S.A.	phase 3	PI3K delta inhibitor	PI3K delta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K/mTOR inhibitor class)

Advagene Biopharma Co. Ltd. · 1 drug in this class
Akron Molecules AG · 1 drug in this class
Allgenesis Biotherapeutics Inc. · 1 drug in this class
Arcus Biosciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AG-73305 — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-73305. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab